Key Companies Covered in the Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Research Report by Research Nester are Cardinal Health Inc., NxThera, Inc., NeoTract, Inc ...

Discover a study where a 30% mean reductions in prostate volume were sustained up to 18 months post-prostate artery ...

Benign Prostatic Hyperplasia, also called BPH, is when a person's prostate gland enlarges with age. Though it affects all men above 40, roughly 50 % need treatment at some point in their lives.

The benign prostatic hyperplasia (BPH) prostate treatment market is anticipated to be worth USD 33,031.10 million in 2024. The market is expected to grow at a steady rate over the period from 2024 to ...

Benign Prostatic Hyperplasia (BPH), or an enlarged prostate, is a common condition in aging men that can cause urinary difficulties, discomfort, and other health issues. TheHealthSite.com ...

Benign Prostatic Hyperplasia (BPH) occurs when the prostate gland grows larger, pressing against the urethra. This pressure narrows the urethra, making it harder for urine to pass through.

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

DELRAY BEACH, Fla., Feb. 17, 2025 /PRNewswire/ -- The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5 ...

Zhang J, Latour CD, Olawore O, et al. Cardiovascular outcomes of α-blockers vs 5-α reductase inhibitors for benign prostatic hyperplasia. JAMA Netw Open. Published online November 14, 2023. doi ...

From left to right: Adam Baumgarten, M.D., Thomas Chi, M.D., James Bryant, M.D. The University of Alabama at Birmingham is growing its robotics portfolio with new technology focused on the treatment ...

Men pharmacologically treated for benign prostatic hyperplasia (BPH) experienced significant improvements in overactive bladder (OAB) symptoms after treatment with vibegron (Gemtesa), according to ...